ENV515 is a fully biodegradable, PRINT®-particle formulation of a marketed prostaglandin analog that has the potential to lower intraocular pressure (IOP) for more than six months from a single extended-release dosage form. ENV515 was designed to address the issue of poor patient compliance that exists today with daily eye drops to limit the progression of glaucoma that sometimes leads to vision loss or blindness. Envisia is also leveraging the PRINT-platform to develop products for other leading ocular diseases, including age-related macular degeneration (AMD) and diabetic macular edema (DME).
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue that has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the Company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/envisia-therapeutics-announces-company-president-dr-ben-yerxa-will-present-at-the-35th-jp-morgan-healthcare-conference-300385330.html
SOURCE Envisia Therapeutics